Patients were randomised ( 2:1:2 ) to liraglutide 1.8 mg once daily ( n = 232 ) , liraglutide placebo ( n = 115 ) and open-label insulin glargine ( n = 234 ) , all in combination with metformin ( 1 g twice daily ) and glimepiride ( 4 mg once daily ) .
